source
- Pfizer adds $2.5 billion to restructuring, targeting $6 billion savings by 2029Pfizer announced an additional $2.5 billion in cost reductions as part of its ongoing restructuring program. The new cuts focus on technology and simplification across commercial, R&D and manufact…
- Analysis questions expanded orphan drug exemptions under recent legislationEd Silverman, a Pharmalot columnist, examined a provision in the One Big Beautiful Bill Act that keeps certain orphan drugs out of Medicare price negotiations. The Inflation Reduction Act, which b…